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Polyphenols and omega‑3 fatty acids are thought to have beneficial effects in Alzheimer’s disease, the most common cause of 
dementia. Seeds of chia (Salvia hispanica L.) are highly rich in these nutrients, and thus, the present study investigated the effects of 
chia seeds on behavior and cognition in an aluminum‑induced Alzheimer’s disease model in rats. Experimental animals received chia 
supplementation either during the generation of the model (i.e., pretreatment) or after the model was established (i.e., treatment). 
A battery of behavioral and cognitive tests were performed, including open‑field, elevated plus maze, Porsolt’s forced swim, and 
Morris’ water maze, to evaluate anxiety‑ and depression‑like behaviors, and learning and memory. Results showed that chia 
supplementation was ineffective against Alzheimer’s‑related anxiety, whereas depression‑like behaviors were attenuated with both 
pretreatment and treatment. There was no improvement in learning and memory with chia treatment. Rather, cognitive performance 
in chia‑pretreated animals was remarkably worse as compared to their non‑treated disease‑induced counterparts. Hippocampal 
concentrations of amyloid‑β42, amyloid precursor protein, and total tau protein were similarly increased in all disease‑induced 
animals (despite chia supplementation), as compared to the controls. Based on these findings, chia supplementation during the 
progression of Alzheimer’s disease may exacerbate the disease. Although the results presented here emerge from an experimental/
preclinical study, we suggest cautious and careful use of chia, especially in early‑stage Alzheimer’s patients, until future research in 
different experimental settings is conducted.
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INTRODUCTION
To date, all of the neurodegenerative diseases, in‑
cluding Alzheimer’s disease, remain without a cu‑
rative treatment. Nevertheless, ceaseless efforts of 
neuroscientists are paving the way with remarkable 
palliative treatment options towards discovering a cu‑
rative treatment. Alzheimer’s disease is the most com‑
mon form of dementia (Alzheimer’s Association 2018). 
Since the first identification of Alzheimer’s disease, 
our knowledge about its pathophysiology has substan‑
tially grown and carried us to the point where we can 
identify and test potential medical and nutritional 
interventions to break the neurodegeneration cycle. 
Among the possible interventions, polyphenols such 
as rosmarinic acid, quercetin, rutin, and caffeic acid 
are extensively studied and shown to possess promis‑
ing antidegenerative actions (Bhullar and Rupasinghe 
2013, Kelsey et al. 2010, Nabavi et al. 2015). In addi‑
tion to polyphenols, several reports underline disease 
relieving features of an omega‑3‑rich diet in Alzhei‑
mer’s (Barberger‑Gateau et al. 2007, Huang et al. 2005, 
Kalmijn et al. 1997). Although clinical data regarding 
benefits of omega‑3 fatty acids in Alzheimer’s disease 
are controversial to some extent (see Canhada et al. 
2017), the systematical review by Hooijmans et al. 
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(2012) suggests that omega‑3 supplementation can al‑
leviate Alzheimer’s pathology in experimental models. 
Hooijmans et al. (2012) also noted that contradictory 
clinical reports likely result from inadequate duration 
of the supplementation.
The seeds of chia (Salvia hispanica L.), a native Lat‑
in American herbaceous plant, are highly rich in the 
abovementioned polyphenols (Pellegrini et al. 2018) as 
well as omega‑3 fatty acids (especially alpha‑linolenic 
acid) (Sargi et al. 2013). These ingredients have caused 
chia seeds to be called a “superfood” and a “functional 
food” (Muñoz et al. 2013, van den Driessche et al. 2018). 
Supplementation with chia seeds is generally considered 
to be safe, with relatively rare and nonspecific adverse 
effects (Ulbricht et al. 2009). In recent years, there has 
been an increase in research regarding health benefits of 
chia, including antioxidant, antiobesogenic, antidiabet‑
ic, cardioprotective, and antitumoral effects. Surprising‑
ly, however, there are no studies examining the effects of 
chia seeds on neurodegenerative diseases and in partic‑
ular, Alzheimer’s disease.
Based on the ingredients of chia seeds, the present 
study was designed to test the hypothesis that chia seed 
supplementation results in antidegenerative effects in 
an experimental model of Alzheimer’s disease. To test 
this hypothesis we investigated cognitive, behavioral 
and Alzheimer’s‑associated parameters in an aluminum 
chloride‑induced disease model.
METHODS
Laboratory conditions and preparations
The study was conducted in the Application and 
Research Center for Experimental Researches at Hatay 
Mustafa Kemal University under standardized labora‑
tory conditions (22±2°C temperature, 55±10% relative 
humidity, 12:12‑h light/dark cycle). The animals were 
provided with ad libitum water and standard or chia‑rich 
pellets. Chia seeds were purchased from local suppli‑
ers, and finely ground and nicely blended in crushed 
standard rat chow [36.2% (w/w)]. Aluminum chlo‑
ride (AlCl3) (Merck, Germany) and D‑galactose (D‑gal) 
(Sigma‑Aldrich, Germany) were dissolved in physiolog‑
ical saline in separate beakers (0.07 M and 0.8 M, respec‑
tively). Chia‑rich pellets were freshly prepared every 
other day, whereas solutions were prepared weekly and 
stored in the refrigerator (4°C). The study was approved 
by the local ethics committee at Hatay Mustafa Kemal 
University (#2017/4‑1 rev.#2018/6‑3).
Experimental design
Adult male Wistar albino rats were randomly as‑
signed into one of four groups: (1) Control (Con, n=8), 
(2) Alzheimer (Alz, n=10), (3) Pretreatment (Pre, n=10), 
and (4) Treatment (Tre, n=10). The animals in Alz, Pre, 
and Tre groups intraperitoneally received 10 mg/kg/day 
AlCl3 and 150 mg/kg/day D‑gal for 21 days whereas the 
Con group received saline injections. The combination 
of AlCl3 and D‑gal was preferred based on previous re‑
ports (Xiao et al. 2011, Chiroma et al. 2018), which note 
that this combination generates pathologies resembling 
to Alzheimer’s disease such as memory deficits, neu‑
ronal loss, increased acetylcholinesterase activity, and 
tauopathy in Wistar albino rats. Con and Alz groups were 
fed standard rat chow throughout the study. The animals 
in the Pre group were fed chia‑rich pellets during the 
induction of the experimental model, whereas the Tre 
group were fed chia‑rich pellets for 21 days following 
the induction. All animals were subjected to a battery of 
behavioral and cognitive tests to evaluate anxiety‑ and 
depression‑like behaviors, and learning and memory. 
The study plan is shown at Fig. 1.
Fig. 1. Study plan. Con: Control, Alz: Alzheimer, Pre: Pretreatment, Tre: Treatment.
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Behavioral and cognitive tests
Open‑field and elevated plus maze tests were per‑
formed to assess anxiety‑like behaviors. Depres‑
sion‑like behaviors were evaluated by using Porsolt’s 
forced swim test. Learning and memory performance 
of the animals was examined by means of Morris’ wa‑
ter maze test. The methods for each test are briefly ex‑
plained below. 
Open‑Field (OF) test
The test apparatus consists of an open‑top 
cube‑shaped box (70x70 cm) which is virtually divided 
to central (40x40 cm) and peripheral zones (30 cm to the 
wall). The animals were gently released into the appa‑
ratus and left to move freely for 5 min. Total distance 
moved (cm), velocity (cm/s) and time in center zone (s) 
were estimated with an animal tracking software (Etho‑
Vision XT, Noldus, The Netherlands) whereas numbers 
of defecations and rearing behaviors were manually re‑
corded. The apparatus was cleaned with 70% ethanol be‑
tween trials to eliminate olfactory cues.
Elevated plus maze (EPM) test
The elevated plus maze test was conducted in 
a plus‑shaped apparatus with two open and two closed 
arms (50x10 cm arms and 10x10 cm center). The closed 
arms were surrounded by opaque walls with the height 
of 50 cm. The animals were gently placed into the appa‑
ratus and left to explore freely for 5 min. Time in open/
closed arms (s) was measured with an animal tracking 
software (EthoVision XT, Noldus, The Netherlands), 
and numbers of rearing and head‑dipping behaviors 
were manually noted. The apparatus was cleaned with 
70% ethanol between trials to eliminate olfactory cues.
Porsolt’s forced swim test
The forced swim test was performed after anxiety 
tests in a cylindrical pool (25 cm dia.) that was filled 
with warm water (25±1°C) to the height of 35 cm. In 
the acclimation (pre‑test) session, the animals were re‑
leased into the pool and left to habituate for 15 min. 
The test session, in which the ethological analysis was 
carried out from video recordings by using a software 
(Behavioral Observation Research Interactive Software, 
Italy) (Friard and Gamba 2016), was conducted 24‑h 
later. In the test session, the animals were allowed to 
swim for 5 min and behaviors except for those required 
to keep the nose above the water surface (i.e., swim‑
ming, climbing, diving) were considered mobility. The 
water was changed and pool was cleaned thoroughly 
between trials.
Morris’ water maze test
A round pool with the diameter of 150 cm was filled 
with warm water (maintained at 25±1°C with water 
heaters) to the height of 50 cm and the water was dark‑
ened with food coloring. A platform was placed 2 cm 
below the water level on one of the virtually designat‑
ed quadrants. The animals were taught the location of 
the platform for 4 consecutive days in learning ses‑
sions. Each learning session was consisted of 4 trials 
with 90 s cut‑off and 30 s inter‑trial interval. On the 
day after the last learning session, the platform was re‑
moved and the animals were left to swim freely for 90 s 
(probe trial). All trials were video‑recorded and latency 
to the platform (s), total distance moved (cm), velocity 
(cm/s), time in the target quadrant (s), distance moved 
in the target quadrant (cm), and average distance to 
the platform zone (cm) were estimated by using a soft‑
ware (EthoVision XT, Noldus, The Netherlands).
Biochemical analyses
The animals were exsanguinated under ketamine/
xylazine (80/12 mg/kg) anesthesia following the be‑
havioral/cognitive tests. The brains were excised and 
hippocampi were dissected on ice. The hippocampal 
tissues were homogenized in a proprietary lysis re‑
agent (T‑PER, Thermo Fisher Scientific, USA) and tissue 
levels of amyloid‑β42, amyloid precursor protein (APP), 
and total tau protein (t‑tau) were measured with com‑
mercial ELISA kits (Elabscience, China) according to the 
instructions of manufacturer. Amyloid‑β42, which ac‑
cumulates in Alzheimer’s disease, is the cleavage prod‑
uct of APP and tau protein is a microtubule‑associated 
protein which is strongly connected with the progres‑
sion of the disease (Kamentani et al. 2018). Bradford’s 
(1976) method was used to quantify total protein con‑
tents. The results were reported as ng/mg protein.
Statistical analyses
Parametric data were analyzed with ordinary or re‑
peated measures one‑way ANOVAs, post‑hoc Tukey’s 
test, or paired Student’s t‑tests, as appropriate. Krus‑
kal‑Wallis test, post‑hoc Dunn’s test, or Mann‑Whitney 
U tests were used for non‑parametric data, as appropri‑
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ate. Results are shown as mean ± standard error of the 
mean (SEM) for parametric data, and 25–75% percen‑
tiles for non‑parametric data. Results were considered 
statistically significant at a p<0.05 threshold.
RESULTS
Body weights and chow consumption
Initial body weights of the animals were similar 
among groups (p>0.05). There was no difference be‑
tween final body weights (data not shown), although 
Tre animals had significantly higher body weight 
change than Alz and Pre groups (F(3,34)=7.21, p=0.001; 
post‑hoc p<0.001 and p=0.035, respectively) (Fig. 2A). 
No significant difference in bod weight was found be‑
tween groups consuming standard vs, chia‑rich chows 
(p>0.05), as depicted in Fig. 2B.
Locomotor activity
The total distance moved and velocity were ex‑
amined for locomotor activity. Both parameters did 
not differ between groups in either open‑field test 
(Fig. 3A, B) or in the probe trial of Morris’ water maze 
test (data not shown).
Anxiety‑like behaviors
We employed the elevated plus maze test to de‑
termine anxiety‑like behaviors. More time spent in 
the open‑arms is thought to reflect lower anxiety‑like 
B
A
Fig. 2. (A) Initial body weights & Δ–Weight (B) Chow consumption. (A) Initial 
body weights are shown with solid bars whereas cumulative body weight 
changes (Δ–Weight) are shown with patterned bars. Asterisks (*) indicate 
significance versus Treatment (p<0.05). (B) There was no statistical sig‑
nificance for the consumption of standard and chia‑rich pellets (p>0.05) 
(Control: Con, Alzheimer: Alz, Pretreatment: Pre, Treatment: Tre).
B
A
Fig. 3. Locomotor activity in the open‑field test. (A) Total distance moved 
and (B) Velocity. There was no statistical significance for either (A) total 
distance moved or (B) velocity (p>0.05) (Control: Con, Alzheimer: Alz, 
Pretreatment: Pre, Treatment: Tre).
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behavior. Compared to the controls, Alz, Pre and Tre 
animals spent significantly less time in the open‑arms 
(F(3,34)=6.9, p=0.001; post‑hoc p=0.037, p<0.001 and 
p=0.006, respectively) and there was no difference be‑
tween these groups (Fig. 4A). Except for rearing, which 
represents exploratory behavior, we did not find statis‑
tically significant differences between groups for other 
ethological measures, including defecation, stretch‑
ing and head‑dipping (data not shown). The number 
of rearing behaviors was significantly lower in the Pre 
group relative to controls (Fig. 4B).
Depression‑like behaviors
As shown at Fig. 5A, in the Porsolt’s forced swim 
test, which was performed to assess depression‑like 
behaviors, Alz animals had significantly lower mobility 
compared to other groups (F(3,34)=5.6, p=0.003; post‑hoc 
p=0.004 vs Con, p=0.032 vs Pre, and p=0.020 vs. Tre). No 
difference in mobility was found between Con, Pre and 
Tre groups (p>0.05). The proportion of climbing time 
(to total mobility) did not between groups (data not 
shown). Since diving had a rare occurrence, it could 
not be analyzed. There were no group differences in 
the number of head twitches (p>0.05) (Fig. 5B).
Learning and memory
The spatial learning and memory performance of the 
animals was evaluated using Morris’ water maze test. As 
depicted at Fig. 6, all groups took gradually less time to 
locate the escape platform in learning trials (RM‑ANO‑
VA, p<0.001), but in the last learning session, controls 
showed significantly faster latency to the platform 
than other animals (KW‑test’s H=17.5, p<0.001; post‑hoc 
B
A
Fig. 4. (A) In the elevated plus maze test, the animals in which the ex‑
perimental Alzheimer’s disease was induced displayed anxiety‑like be‑
haviors, but neither pretreatment nor treatment with chia seeds had 
any effect on these behaviors. (B) Exploratory behavior, inferred from 
the number of rearing, was decreased in chia‑pretreated animals. As‑
terisks (*) indicate significance versus Control, and section sign (§) ver‑
sus Treatment (p<0.05). (Control: Con, Alzheimer: Alz, Pretreatment: 
Pre, Treatment: Tre).
B
A
Fig.  5. (A) Mobility and (B) Number of head twitches in the Porsolt’s 
forced swim test. (A) Non‑treated disease‑induced animals exhibited 
significantly less mobility than both controls and chia‑supplemented 
groups. Asterisk (*) indicates significance versus Control, and section 
sign (§) versus Alzheimer (p<0.05). (B) There was no statistical signifi‑
cance for the number of head twitches between groups (p>0.05) (Con‑
trol: Con, Alzheimer: Alz, Pretreatment: Pre, Treatment: Tre).
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p=0.037 vs. Alz, p<0.001 vs. Pre, and p=0.003 vs. Tre), In 
addition, the Pre group took longer to find the platform 
compared to Alz group (p=0.036). In the probe trial, the 
time spent in the target quadrant, which is interpreted 
as the main measure of memory retention, was signifi‑
cantly greater in controls than other animals. Further‑
Fig. 6. Learning trials of the Morris’ water maze test. All animals gradually showed better performance at finding the platform; however, con‑
trols spent significantly lesser time than others in the last learning trial. Different letters in each group indicate statistical significance between 
learning sessions (in‑group comparison) (p<0.05). Asterisks (*) indicate significance between groups shown with arrow begin and end in each day 
(inter‑group comparison) (p<0.05) (Control: Con, Alzheimer: Alz, Pretreatment: Pre, Treatment: Tre).
A B
C
Fig. 7. (A) The time spent in the target quadrant, (B) Ratio of in‑target distance to total distance moved and (C) Average distance to the platform 
zone. (A) Disease‑induced animals, either chia supplemented or not, spent lesser time than controls in the target quadrant. Also, the animals 
pretreated with chia elapsed less time in the target quadrant compared to non‑treated disease‑induced animals. Both for (B) the proportional 
in‑target distance and (C) distance to the platform zone, the results were alike. Asterisks (*) indicate significance versus Control, and section sign 
(§) versus Alzheimer (p<0.05) (Control: Con, Alzheimer: Alz, Pretreatment: Pre, Treatment: Tre).
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more, the Pre group spent less time than Alz and Tre 
groups in the target quadrant, as illustrated at Fig. 7A. 
Results for additional parameters were consistent with 
these results, specifically the ratio of distance moved 
in the target quadrant to total distance moved (Fig. 7B; 
F(3,34)=13.6, p<0.001; post‑hoc Con vs. Alz: p=0.044, Con vs. 
Pre: p<0.001, Con vs. Tre: p<0.001, Alz vs. Pre: p=0.006) 
and the average distance to the platform zone (Fig. 7C; 
F(3,34)=11, p<0.001; post‑hoc Con vs. Alz: p=0.049, Con vs. 
Pre: p<0.001, Con vs. Tre: p=0.009, Alz vs. Pre: p=0.016).
Biochemical measurements
As shown at Fig. 8A, the hippocampal concentrations 
of amyloid‑β42 were higher in Alz, Pre and Tre animals 
as compared to controls (KW‑test’s H=14.6, p=0.002; 
post‑hoc p<0.001, p=0.017 and p=0.002, respectively). 
As expected, the concentration of APP was similarly 
increased in the experimental Alzheimer’s disease‑in‑
duced groups (KW‑test’s H=8.4, p=0.038; post‑hoc Con vs. 
Alz: p=0.012, Con vs. Pre: p=0.031 and Con vs. Tre: p=0.011) 
(Fig. 8B). Also, higher amounts of t‑tau were found in Alz, 
Pre and Tre groups as compared to Con group (KW‑test’s 
H=15.2, p=0.002; post‑hoc p=0.001, p<0.001 and p=0.007, 
respectively) (Fig. 8C). There was no difference between 
Alz, Pre and Tre animals in regard to aforementioned 
hippocampal measurements (p>0.05).
DISCUSSION
The present study investigated the behavioral and 
cognitive effects of chia‑rich feeding in rats, using an 
aluminum chloride‑induced experimental Alzheimer’s 
disease model. Our main results can be summarized as 
follows: the disease (i) generated anxiety‑like behaviors, 
but neither pretreatment (i.e., supplementation while 
the model is being established) nor treatment (i.e., sup‑
plementation after the model is established) with chia 
had any anxiolytic effects, (ii) provoked depression‑like 
behaviors, and both pretreatment and treatment alle‑
viated depressive behaviors, (iii) impaired the learning 
and memory performance of animals, and pretreat‑
ment (but not treatment) exacerbated the impairment 
in learning and memory, and (iv) increased the hippo‑
campal concentrations of Alzheimer’s‑associated pa‑
rameters [amyloid‑β42, APP and t‑tau] which remained 
elevated with pretreatment or treatment.
Modern humans are inevitably exposed to alumi‑
num through polluted air, contaminated diet, medi‑
cations, and even the skin (Exley 2013). Although this 
environmental exposure is believed to be in minute 
amounts (Campbell 2002), aluminum has been shown to 
accumulate in aging neurons due to lifetime exposure 
(Walton 2006). Previous studies also show elevated lev‑
els of aluminum in the brains and cerebrospinal fluid 
of Alzheimer’s disease patients (Virk and Eslick 2015). 
Several authors have emphasized the role of chron‑
ic aluminum exposure in the pathophysiology of Alz‑
C
B
A
Fig.  8. Hippocampal concentrations of (A) Amyloid‑β42, (B) Amyloid 
precursor protein and (C) Total tau protein. Controls had significantly 
lower concentrations of amyloid‑β42, APP, and t‑tau. There was no 
difference between disease‑induced animals. Asterisks (*) indicate 
significance versus Treatment (p<0.05) (Control: Con, Alzheimer: Alz, 
Pretreatment: Pre, Treatment: Tre).
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heimer’s disease (Gupta et al. 2005, Wang et al. 2016); 
however, no direct evidence exists that supports or 
rejects a causal relationship between these variables. 
Nevertheless, the existing experimental data indicate 
that aluminum‑based experimental models show neu‑
ronal alterations that resemble those observed in Alz‑
heimer’s disease (Castorina et al. 2010, Shaw and Toml‑
jenovic 2013, Walton 2007, 2014).
A significant proportion of Alzheimer’s patients suf‑
fer from comorbid affective disorders, even though the 
disease is fundamentally a memory deteriorating dis‑
ease (Even and Weintraub 2010, Novais and Starkstein 
2015). Affective disorders and Alzheimer’s disease seem 
to be reciprocally linked based on abnormal myelin‑
ation (Nihonmatsu‑Kikuchi et al. 2013). Furthermore, 
they share some other similar neuroimmunologic, neu‑
roendocrine and oxidative disturbances (Rodrigues et 
al. 2014). Despite these similarities, depressive symp‑
toms are not correlated with the severity of Alzhei‑
mer’s disease, which suggests distinct pathophysio‑
logical mechanisms (Lee and Lyketsos 2003). Hence, an 
intervention that relieves depression is not expected to 
have antidegenerative efficacy in Alzheimer’s disease. 
Despite an extensive literature search, we are aware 
of only a few reports examining the behavioral and 
cognitive effects of chia seeds. In the behavioral study 
by Nemeth et al. (2014), which was conducted in guin‑
ea pigs, no influence of chia seeds on locomotion was 
reported. These results are in accordance with our own 
data in rats. Although depression‑like behaviors were 
not evaluated in the study by Nemeth et al. (2014), sa‑
liva cortisol concentrations were found to be lower in 
chia‑supplemented animals. Cortisol is physiologically 
a stress confronting hormone, but in depression, dys‑
regulated hypothalamic‑pituitary‑adrenal (HPA) axis 
response leads to increased cortisol levels, which can 
be reduced by antidepressants (Maric and Adzic 2013). 
Although cortisol is not a depression marker by itself, 
but rather an associated hormone, the observed anti‑
depressant‑like effects of chia in the present study may 
be derived from its action on the HPA axis. Also, the 
finding of ineffectiveness of chia supplementation on 
social stress in the study of Nemeth’s team may be in‑
terpreted as absence of any influence on anxiety‑like 
behaviors, which is also similar to our results.
Regarding the cognitive effects of chia seeds, a re‑
cent nutritional intervention trial was conducted in 
undergraduate students by Onneken (2018). The au‑
thor founds an improvement in both memory and in‑
telligence tests following chia seed supplementation 
(5 g/day) for 21 days. Based on these results, the au‑
thor of the study concluded that “chia consumption is 
highly recommendable for dealing with Alzheimer’s 
disease”, despite the fact that the included partici‑
pants were all young, healthy individuals (average age: 
21.3 years). Our results instead suggest that chia seeds 
while an experimental Alzheimer’s disease is progress‑
ing tremendously impairs learning and memory. We 
also found no benefit of chia seed supplementation af‑
ter the disease has already emerged. Recently, Rui et al. 
(2018) reported similar findings in a senescence‑accel‑
erated mouse‑prone 8 mouse line, which displays the 
phenotype of accelerated aging. In their study, they 
emphasized the absence of cognitive improvement 
with chia supplementation and increased activity in 
both amyloidogenic and non‑amyloidogenic pathways, 
which subsequently bolstered the amyloid pathology. 
The ineffectiveness of chia in cognitive improvement 
was also confirmed in male guinea pigs by Nemeth et 
al. (2015). Undoubtedly, it is clear that experimental/
preclinical researches cannot be directly extrapolat‑
ed to clinical practice; however, these studies are in‑
valuable in terms of translational medicine, especially 
where scant knowledge exists.
To further explain our cognitive findings, we should 
revisit the chemical properties of aluminum. Alumi‑
num is a prooxidant, but redox‑inactive metal. Exley 
(2004) and Ruipérez et al. (2012) have attributed the 
prooxidant potency of aluminum, in part, to its iron 
reducing action. Aluminum stimulates iron overload in 
tissues by altering the cellular uptake of iron (Cannata 
Andia 1996). Polyphenols, which are generally known 
antioxidants, exert prooxidant activity in this reduced 
iron‑enriched medium (Decker 1997, Margină et al. 
2015, Osborn and Akoh 2003). Given that chia seeds 
are highly rich in omega‑3 fatty acids and polyphe‑
nols, this study was designed to observe chia’s effects 
on both progressing and already emerged disease. We 
found that the learning and memory impairing effect 
of chia is apparent in animals in which the disease 
was progressing, but not in those in which the disease 
has already emerged. We hypothesize that this result 
may be due to the prooxidation favoring environment. 
Presumably, the animals in which the disease already 
emerged had time to excrete aluminum and were able 
to escape from its devastating consequences. Further‑
more, these animals may have had a positive energy 
balance via the help of increased beta‑oxidation of 
alpha‑linoleic acid (Fu and Sinclair 2000). In this con‑
text, how can our results of Alzheimer’s‑associated bio‑
chemical parameters be interpreted? Indeed, amyloid/
tau hypothesis is insufficient to completely explain the 
pathophysiology, although amyloidogenic accumula‑
tion remains to be a prominent feature of the disease 
(Kametani and Hasegawa 2018). Hence, one should also 
consider other hypothesis, including oxidative stress. 
Therefore, no change in these parameters in our study 
supports the assumption of prooxidant action of the 
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chia supplementation within the perspective of the ox‑
idative hypothesis.
Although this is the first study to examine the be‑
havioral and cognitive effects of chia seeds in an exper‑
imental Alzheimer’s disease model, it has some limita‑
tions that should be taken into account when interpret‑
ing results. Although we demonstrated an impairment 
in learning and memory with chia supplementation, 
we speculate without any relevant analysis that this 
impairment may be the result of oxidative stress. We 
also restricted our analyses to basic Alzheimer’s‑asso‑
ciated biochemical parameters. Further examination, 
probably including of the cholinergic pathway, protein 
modifications, neuroimmune reactions and neuromod‑
ulations, are needed to clarify the exact mechanism(s). 
Next, we employed an aluminum‑induced model, which 
is reported to resemble the pathophysiological features 
of Alzheimer’s disease; however, our results need to be 
confirmed in other non‑transgenic and transgenic mod‑
els before deprecating chia supplementation in patients 
with Alzheimer’s disease. Nonetheless, based on the 
knowledge of the neuronal accumulation of aluminum 
in Alzheimer’s disease, we suggest cautious and careful 
use of chia supplementation – particularly in early‑stage 
patients whose disease is progressing – until further re‑
search in different experimental settings is conducted.
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